Abbott Receives FDA Approval For HUMIRA As Treatment For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis - Quick Facts
Friday, January 18, 2008; Posted: 04:33 PM
(RTTNews) - Abbott (
ABT |
news |
PowerRating |
PR Charts ) said on Friday that it has received U.S. Food and Drug Administration approval to market HUMIRA or adalimumab as a treatment for adult patients with moderate to severe chronic plaque psoriasis. The approval is based on two pivotal trials, REVEAL and CHAMPION, which showed that nearly 3 in 4 patients achieved 75% clearance or better at week 16 of treatment, compared to placebo.
The drug was approved for moderate to severe rheumatoid arthritis in 2002, psoriatic arthritis in 2005, ankylosing spondylitis in 2006, and moderate to severe Crohn's disease in 2007.
For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved
Morning Coffee with TradingMarkets -- Free Newsletter
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
Email Article Link
Close X
